• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Clearmind Medicine Inc (NQ: CMND )

    1.360 -0.040 (-2.86%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 10, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,669,070
    Open 1.300
    Bid (Size) 1.230 (11)
    Ask (Size) 1.300 (56)
    Prev. Close 1.400
    Today's Range 1.250 - 1.380
    52wk Range 0.9205 - 10.35
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Clearmind Medicine Files International Patent For Ibogaine Combination Therapy
    Clearmind Medicine filed an international patent for a treatment that aims to enhance addiction treatment safety and efficacy. 
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property

    Performance

    YTD
    -51.08%
    -51.08%
    1 Month
    +2.26%
    +2.26%
    3 Month
    -15.53%
    -15.53%
    6 Month
    +6.25%
    +6.25%
    1 Year
    -79.97%
    -79.97%

    More News

    Read More
    Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
    From SciSparc Ltd
    Via GlobeNewswire
    Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Could Psychedelics End Binge Drinking? A Breakthrough Patent Says Yes
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
    From SciSparc Ltd
    Via GlobeNewswire
    Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Nasdaq Edges Lower; Morgan Stanley Earnings Top Views
    Via Benzinga
    Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Crude Oil Down 1%; Bank of America Posts Upbeat Earnings
    Via Benzinga
    Exposures Fossil Fuels
    Why Is SciSparc (SPRC) Stock Up 25% Today?
    Via InvestorPlace
    Topics Intellectual Property
    Exposures Intellectual Property
    Dow Jumps 400 Points; US Retail Sales Flat For June
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
    From SciSparc Ltd
    Via GlobeNewswire
    Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.